ema glp-1 vision loss recommendation 2025 Warns of Risk from Semaglutide Eye Condition a 'Very Rare'

After three months of semaglutide treatment, the patient reported weight loss (from 87 to 82 kg) and a slight decrease in thirst and water intake, but no change in urinary frequency (Table 1)

Designed for Metabolic & Neurological Optimization A complete cellular therapynot just hydration

Sowa says

Understanding 5 Amino-1MQ: 5 Amino-1MQ is a novel molecule thats turning heads due to its role in inhibiting the enzyme NNMT (Nicotinamide N-methyltransferase)

Central to this shift is the recognition that intestinal reparative therapy, defined by objective endpoints such as endoscopic and histologic healing, is strongly associated with improved long-term outcomes